Literature DB >> 2787334

Reliable confirmation of antibodies to human immunodeficiency virus type 1 (HIV-1) with an enzyme-linked immunoassay using recombinant antigens derived from the HIV-1 gag, pol, and env genes.

V L Ng1, C S Chiang, C Debouck, M S McGrath, T H Grove, J Mills.   

Abstract

An enzyme-linked immunoassay (ELISA) using six recombinant proteins corresponding to large segments of the human immunodeficiency virus type 1 (HIV-1) gag, pol, and env gene products (HIVAGEN; SmithKline Bio-Science Laboratories, Van Nuys, Calif.) was developed to confirm the presence of antibodies to HIV-1 in sera reactive in the whole-cell-derived virion screening ELISAs. Serum samples for testing were obtained from healthy seronegative blood donors and from the different categories of HIV-infected individuals (asymptomatic, acquired immunodeficiency syndrome [AIDS]-related complex, and AIDS). A positive reaction was defined as reactivity against an env and at least one other (either gag or pol) HIV-1 gene product; negative was defined as no reaction with any antigen; and indeterminate was defined as reactivity with gag or pol (or both) or with env alone. None of the 1,180 serum samples from healthy seronegative blood donors gave a positive result, and only 49 of these samples (4%) gave indeterminate results. The recombinant HIV-1 antigen ELISA panel identified seropositive individuals with a high degree of accuracy, as a positive reaction was seen with 99.3% of asymptomatic healthy seropositive individuals, 98.1% of patients with AIDS-related complex, and 90.4% of patients with AIDS. None of the 725 HIV-1-seropositive subjects had a negative test result. Reactivity with the Kp41 antigen, corresponding to an amino-terminal portion of the gp41 envelope glycoprotein, by itself demonstrated 100% sensitivity and specificity in distinguishing seronegative from seropositive sera. A subset of seronegative and seropositive samples were tested both with the recombinant HIV-1 antigen ELISA panel and by Western blot (Du Pont Co.). The recombinant HIV-1 antigen ELISA panel accurately identified more seropositive and seronegative samples and had fewer indeterminate results than did Western blot (interpreted by Du Pont criteria).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787334      PMCID: PMC267466          DOI: 10.1128/jcm.27.5.977-982.1989

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  39 in total

1.  Licensed tests for antibody to human T-lymphotropic virus type III. Sensitivity and specificity.

Authors:  J C Petricciani
Journal:  Ann Intern Med       Date:  1985-11       Impact factor: 25.391

2.  False positive anti-HTLV III serology.

Authors:  T J Neale; J Dagger; R Fong; M Humble; P Meech; P J Hatfield; R B Morrison
Journal:  N Z Med J       Date:  1985-10-23

3.  HIV/HTLV gene nomenclature.

Authors:  R Gallo; F Wong-Staal; L Montagnier; W A Haseltine; M Yoshida
Journal:  Nature       Date:  1988-06-09       Impact factor: 49.962

4.  Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications.

Authors:  S H Weiss; J J Goedert; M G Sarngadharan; A J Bodner; R C Gallo; W A Blattner
Journal:  JAMA       Date:  1985-01-11       Impact factor: 56.272

5.  Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS.

Authors:  J Schüpbach; O Haller; M Vogt; R Lüthy; H Joller; O Oelz; M Popovic; M G Sarngadharan; R C Gallo
Journal:  N Engl J Med       Date:  1985-01-31       Impact factor: 91.245

6.  Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome.

Authors:  G M Shaw; B H Hahn; S K Arya; J E Groopman; R C Gallo; F Wong-Staal
Journal:  Science       Date:  1984-12-07       Impact factor: 47.728

7.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

8.  Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion.

Authors:  D A Cooper; J Gold; P Maclean; B Donovan; R Finlayson; T G Barnes; H M Michelmore; P Brooke; R Penny
Journal:  Lancet       Date:  1985-03-09       Impact factor: 79.321

9.  Identification and antigenicity of the major envelope glycoprotein of lymphadenopathy-associated virus.

Authors:  L Montagnier; F Clavel; B Krust; S Chamaret; F Rey; F Barré-Sinoussi; J C Chermann
Journal:  Virology       Date:  1985-07-15       Impact factor: 3.616

10.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.

Authors:  J A Levy; A D Hoffman; S M Kramer; J A Landis; J M Shimabukuro; L S Oshiro
Journal:  Science       Date:  1984-08-24       Impact factor: 47.728

View more
  6 in total

Review 1.  More reliable diagnosis of infection with human immunodeficiency virus type 1 (HIV-1) by detection of antibody IgGs to pol and gag proteins of HIV-1 and p24 antigen of HIV-1 in urine, saliva, and/or serum with highly sensitive and specific enzyme immunoassay (immune complex transfer enzyme immunoassay): a review.

Authors:  S Hashida; K Hashinaka; S Ishikawa; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

2.  Development and evaluation of a human T-cell leukemia virus type I serologic confirmatory assay incorporating a recombinant envelope polypeptide.

Authors:  E P Lillehoj; S S Alexander; C J Dubrule; S Wiktor; R Adams; C C Tai; A Manns; W A Blattner
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

3.  Continuous epitopes of the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein and reactivity of human sera to synthetic peptides representing various HIV-1 isolates.

Authors:  P Horal; B Svennerholm; S Jeansson; L Rymo; W W Hall; A Vahlne
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

4.  Expression in Escherichia coli and sequencing of the coding region for the capsid protein of Dutch maedi-visna virus strain ZZV 1050: application of recombinant protein in enzyme-linked immunosorbent assay for the detection of caprine and ovine lentiviruses.

Authors:  R G Zanoni; I M Nauta; U Pauli; E Peterhans
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

5.  Detection of antibodies to caprine arthritis-encephalitis virus using recombinant gag proteins.

Authors:  E Rimstad; N East; E DeRock; J Higgins; N C Pedersen
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

6.  Immune complex transfer enzyme immunoassay that is more sensitive and specific than western blotting for detection of antibody immunoglobulin G to human immunodeficiency virus type 1 in serum with recombinant pol and gag proteins as antigens.

Authors:  S Hashida; K Hashinaka; I Nishikata; S Oka; K Shimada; A Saito; A Takamizawa; H Shinagawa; S Yano; H Kojima
Journal:  Clin Diagn Lab Immunol       Date:  1995-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.